Sage Therapeutics’ stock tanks as Phase III depression study misses primary endpoint
In a call with investment bank analysts, executives said the trial was nevertheless not a failure and said the trial was supportive of a generalized filing in major depressive disorder, particularly when factoring in data on disease severity and noncompliance.